Ocular Biomarker Services ace

Omics-Based Ocular Biomarker Discovery and Analysis Services

Ocular biomarker discovery and identification is a multi-step and iterative process, and ideal ocular biomarkers can serve as intermediate markers of disease in clinical trials and possible drug targets. Ace Therapeutics has a team of professionals helping you build a robust biomarker analysis strategy through all phases of development, starting early in the drug discovery phase. Whatever your research purpose, we will provide the highest quality solutions.

What is Ocular Biomarkers Discovery?

Biomarkers are used to measure the response of biological fluids, cells, and tissues, providing important information about safety and efficacy during drug discovery and development. Discovering and screening suitable biomarkers is used in research to design and develop more effective therapies to help guide decisions about which drug candidates to further develop. Ace Therapeutics' ocular biomarker discovery and analysis incorporates proteomics, genomics, and metabolomics into the workflow to accelerate the drug development process.

Fig.1. Multi-omics approach to identify biomarkers for retinal vascular diseases. (Lei Y, et al., 2022)

Our Services

Ace Therapeutics is a comprehensive ophthalmology preclinical CRO. Our comprehensive ocular biomarker discovery and screening services will help you screen for any biomarkers that may help your research, whether they are specific in any matrix of the eye molecules (such as proteins, gene sequences, or expressed RNA). Our biomarker discovery program finds the most valuable ocular biomarkers by investigating cellular, proteomic, metabolomic and genetic sources.

With advanced analysis platforms, a large number of technologies and methods have been used by our scientists to study and discover biomarkers, including mass spectrometry, proteomics, genomics, metabolomics and epigenetic methods, etc. Apart from this, other techniques used in biomarker discovery include in vitro analysis of DNA/RNA expression, protein expression and metabolite quantification. Morphological and functional imaging techniques can also be used to measure biological processes in vivo. Different methods generate large amounts of data to be parsed to obtain your target object.

Do you want to identify new biomarkers? We accelerate your research from hypothesis to candidate validation! Ace Therapeutics provides the following ocular biomarker discovery strategies including but not limited to.

Proteomic-Based Ocular Biomarker Discovery and Analysis Services

Proteomic-Based Ocular Biomarker Discovery and Analysis Services >>

Proteins are critical functional parts of an organism and reflect what is occurring in that organism. It is possible to identify relevant biomarkers and predict ocular disease progression by monitoring the protein of interest and its post-translational state. Our scientists will interrogateogate your biological sample to identify potential biomarkers that a proteomic profile would yield.

Genomics-Based Ocular Biomarker Discovery and Analysis Services >>

Both gene expression and the presence of specific gene sequences can be used as biomarkers for many diseases (such as eye diseases), and treatment regimens could even be tailored for individual patients based on these genomic biomarkers. Our scientists conduct large-scale ocular gene expression studies to identify genes that are up- or down-regulated in specific indications or diseases. These studies rely on the specialized knowledge of our researchers, as well as powerful software tools to analyze the resulting data and identify potential biomarkers.

Genomics-Based Ocular Biomarker Discovery and Analysis Services

Metabolomics-Based Ocular Biomarker Discovery and Analysis Services

Metabolomics-Based Ocular Biomarker Discovery and Analysis Services >>

Metabolomics can qualitatively and quantitatively detect pathophysiological stimuli or all low-molecular-weight metabolites after modification, and capture comprehensive analytes that characterize human phenotypes and their complex metabolic processes in real time. Our scientists use nuclear magnetic resonance technology and ultra-high performance liquid chromatography combined with quadrupole/time-of-flight tandem mass spectrometry (UPLC-Q/TOF-MS/MS) to analyze the changes in endogenous metabolites, and can find new biomarkers for early diagnosis of eye diseases, and explore the pathogenesis of diseases.

Epigenomic-Based Ocular Biomarker Discovery and Analysis Services >>

Epigenetics relies on the modification of gene expression induced by changes in the environment without altering DNA structure. Epigenetic changes now known to be associated with eye disease include DNA methylation, histone and non-histone post-translational modifications, and non-coding RNA regulators. Ace Therapeutics' consulting science has a deep understanding of the genetic mechanisms associated with ocular biomarkers and is able to use a range of cutting-edge epigenetic techniques combined with informatics to identify the genetic and environmental determinants of common and complex eye disorders. This can help clients identify potential biomarkers more quickly.

Epigenomic-Based Ocular Biomarker Discovery and Analysis Services

Lipidomics-Based Ocular Biomarker Discovery and Analysis Services

Lipidomics-Based Ocular Biomarker Discovery and Analysis Services >>

Lipids play a key role in many physiological pathways and can be used as biomarkers of disease or as therapeutic targets to treat diseases. Lipidomics research can analyze different lipid molecules in biological samples to better understand ocular disease and develop novel biomarkers for early detection and diagnosis, treatment, progression and prognosis. Ace Therapeutics' scientists use shotgun lipidomics and liquid chromatography-mass spectrometry to help customers better screen for ocular lipidome biomarkers and advance research programs.

Ocular Cell Biomarkers Discovery and Analysis Services >>

Ace Therapeutics dedicated team has the ability to discover new and rare cell types through multiparametric analysis, enabling more detailed characterization of cell populations and identification of subpopulations as markers of disease. Utilizing genomic and proteomic analysis to provide pure populations, these cells are easily and reliably isolated for downstream analysis, further supporting ocular cell biomarker workflows.

Ocular Cell Biomarkers Discovery and Analysis Services

Ocular Tissue Biomarker Discovery and Analysis Services

Ocular Tissue Biomarker Discovery and Analysis Services >>

An increasing number of tissue biomarkers that can target cells, tissue morphology, and protein expression have been used in clinical practice. These biomarkers have been used to aid in disease diagnosis, assess patient prognosis, and formulate treatment plans by predicting individual patient responses to treatments. Ace Therapeutics' scientists rely on experience with automated homogenization, manual homogenization, homogenization buffer optimization, and species and tissue types to help our partners discover potential tissue biomarkers.

Why Choose Us?

Provide powerful detection methods and analysis methods that can be easily transferred across multiple platforms.
Provide mechanism-of-action studies that can be linked to new therapeutic targets.
Across multiple eye disease areas.

Thanks to strong professional knowledge and advanced technology platforms, Ace Therapeutics offers comprehensive eye biomarker discovery and screening services. Our professional biomarker service team will determine the most suitable solution for your project based on your specific requirements.If you are interested in our services, please feel free to contact us.

Reference

Lei Y, Guo J, He S, et al. Essential Role of Multi-Omics Approaches in the Study of Retinal Vascular Diseases. Cells. 2022;12(1):103.

For Research Use Only.

Get in Touch